Abstract: A composition comprising: a) a compound of Formula (I), ?or a salt, co-crystal or solvate thereof; and b) at least one chemotherapeutic agent, or a salt, co-crystal or solvate thereof, suitable for use in the treatment of breast cancer, preferably triple negative breast cancer.

Abstract: A composition comprising: a) a compound of Formula (I), ?or a salt, co-crystal or solvate thereof; and b) at least one chemotherapeutic agent, or a salt, co-crystal or solvate thereof, suitable for use in the treatment of breast cancer, preferably triple negative breast cancer.

Abstract: A composition for use in the prevention and/or treatment of colorectal cancer in a patient, comprising: a) a compound of Formula (I), where R1, R2, and R3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof; R5, R6, R7, R8, R9 and R10 are, each one and independently, hydrogen, hydroxyl or an —OR4 group, where R4 is a protector group according to the previous definition; and b) at least one chemotherapeutic agent.

Abstract: A composition comprising a) a compound of Formula (I), where R1, R2, and R3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof, R5, R6, R7, R8, R9 and R10 are, each one and independently, hydrogen, hydroxyl or an —OR4 group, where R4 is a protector group according to the previous definition; and b) at least one chemotherapeutic agent, suitable for use in the treatment of Breast Cancer.

Abstract: A composition for use in the prevention and/or treatment of colorectal cancer in a patient, comprising: a) a compound of Formula (I), where R1, R2, and R3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof; R5, R6, R7, R8, R9 and R10 are, each one and independently, hydrogen, hydroxyl or an —OR4 group, where R4 is a protector group according to the previous definition; and b) at least one chemotherapeutic agent.

Abstract: A composition comprising a) a compound of Formula (I), where R1, R2, and R3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof, R5, R6, R7, R8, R9 and R10 are, each one and independently, hydrogen, hydroxyl or an —OR,? group, where R4 is a protector group according to the previous definition; and b) at least one chemotherapeutic agent, suitable for use in the treatment of Breast Cancer.

Abstract: Methods for treating cancer by using compound PM00104, in particular, for treating multiple myeloma are provided.

Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other titumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.

Abstract: Methods for treating cancer by using compound PM00104, in particular, for treating multiple myeloma are provided.

Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.

Abstract: Procedure for the study of the functional activation of leukocytes, platelets and other cells, produced in vivo or induced in vitro, based on the stabilization of cytoplasmic membrane proteins and its detection using quantitative cytometric methods in the absence of any further manipulation of the sample. The procedure includes the sequential incubation of the sample with: 1) either one or a mixture of more than one protease specific inhibitors and, 2) a combination of several fluorochrome-conjugated monoclonal antibodies; to analyze the expression of surface proteins using immunofluorescence methods and quantitative cytometry.